Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. (APR)
This study is currently recruiting participants.
Verified July 2017 by INC Research
First Posted: November 29, 2006
Last Update Posted: July 6, 2017
Hetero Labs Ltd.
Janssen Scientific Affairs
Lupin Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Prinston Pharmaceutical Inc.
Ranbaxy Inc., a SunPharma Co.
Sciegen Pharmaceuticals Inc.
Silarx Pharmaceuticals Inc
Strides Shasun Ltd.
Teva Pharmaceuticals USA
Amneal Pharmaceuticals, LLC
Dr. Reddy's Laboratories UK Ltd.
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||January 2099|
|Estimated Primary Completion Date:||January 2099 (Final data collection date for primary outcome measure)|